CERC-501

Phase 2Small molecule

Johnson & Johnson

CERC-501 is one of 41 small molecule programs targeting Smoking Behavior. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Smoking BehaviorActive, not recruiting

AnxietyActive, not recruiting

Smoking BehaviorPhase 2

Active, not recruiting

AnxietyPhase 2

Active, not recruiting

Competition

Competitive Landscape

165 competitors in Anxiety

#DrugCompanyPhaseTrials

Circadin

NNeurim Pharmaceuticals Ltd.

Phase 3

4 2

Duragesic

CCephalon

Phase 3

1 3

Centanafadine

Otsuka

Phase 3

1 4

Celexa

AbbVie

Preclinical

1 5

Spravato

WWim Janssens

Preclinical

4 6

Campral

FForest Laboratories

Preclinical

2 7

Luvox

SSolvay Pharmaceuticals

Preclinical

2 8

Anerem

AAcacia Pharma Ltd

Preclinical

2 9

CERC-501

Johnson & Johnson

Phase 2

1 10

Sufenta

LLeaf Vertical Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Smoking1 trial

Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?

Completed·YYale University·Phase 2·NCT02800928·17 enrolled

Treatment Resistant Depression1 trial

Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression

Terminated·MMassachusetts General Hospital·Phase 2·NCT01913535·8 enrolled

Smoking Behavior1 trial

A Study in a Human Laboratory Model of Smoking Behavior

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT02641028·71 enrolled

Anxiety1 trial

Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2a

Completed·—·Phase 2·NCT02218736·163 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for CERC-501. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CERC-501 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CERC-501. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Johnson & Johnson

CERC-501

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Smoking1 trial

Treatment Resistant Depression1 trial

Smoking Behavior1 trial

Anxiety1 trial

References

Drug Info

Quick Facts

Related News